SAN FRANCISCO--(BUSINESS WIRE)--Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the company has appointed Jessica Grossman, M.D., as its Chief Executive Officer, effective immediately. Dr. Grossman has been chair of the Board of Directors of Alliance Partners360, Medicines360’s for-profit subsidiary, since 2014 and a director of Medicines360 since 2011.
“Jessica is a seasoned industry executive and medical technology pioneer with a proven track record at women's health care companies. She brings a wealth of experience in product development and commercialization, coupled with the ability to move quickly and nimbly to accelerate product offerings,” said Dr. Victoria Hale, Founder and Board Member of Medicines360. “Her leadership, vision and entrepreneurial background will be invaluable assets to Medicines360 as the company transforms from development and commercialization of its first product and moves to the next chapter of expanded product growth and global leadership in women’s health.”
Dr. Grossman most recently served as president and CEO of Sense4Baby, Inc., a start-up company that developed an innovative, wireless maternal/fetal heart rate monitoring system for women with high-risk pregnancies. During her tenure, the company closed a $4 million Series A investment and she rapidly led the company to a successful acquisition following U.S. Food and Drug Administration (FDA) approval, CE mark and commercialization of the company’s lead product within 18 months of joining the organization. In addition, Dr. Grossman was founder and president of Gynesonics, an early-stage medical device company focused on minimally invasive solutions for women’s health. She raised more than $22 million in venture capital financing and invented and helped develop the first intrauterine, ultrasound-guided radiofrequency ablation device for fibroid tumors, a common disorder in women. Dr. Grossman was also a medical director at Ethicon Endo-Surgery, a part of the Johnson & Johnson family of companies.
“I am thrilled by the opportunity to take on this leadership role at Medicines360 at a pivotal time in the company’s evolution. As CEO, my top priorities will be building a robust pipeline of women’s health products and strengthening our partnership relationships for long-term sustainability,” said Dr. Grossman. “Medicines360 is a groundbreaking company seeking to expand access, educate and improve the lives of women in the U.S. and around the world. The company was founded by visionary Victoria Hale Ph.D., with a mission to provide all women with the ability to access and choose quality medicines, regardless of their socioeconomic status, insurance status, or geographic location. I am honored to follow Victoria and I share her commitment and passion for women’s health. I look forward to helping the company advance innovative medical solutions and a better future for all women, regardless of their insurance coverage or where they live.”
Dr. Grossman earned a Medical Degree from Thomas Jefferson University in Philadelphia and an undergraduate degree with honors from Brandeis University. She also has performed research at the Beth Israel Deaconess Medical Center, one of the teaching hospitals of Harvard Medical School.
Medicines360, located in San Francisco, California, is an innovative nonprofit global women’s health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance status or geographic location. Medicines360 was founded in 2009 and introduced its first product, a progestin intrauterine device (IUD) in February 2015 with the goal of expanding access. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need.
For more information, visit www.medicines360.org.